Elizabeth M. Richards > Latham & Watkins LLP > San Francisco, United States > Lawyer Profile
Latham & Watkins LLP Offices

505 MONTGOMERY STREET
SUITE 2000
SAN FRANCISCO, CA 94111-6538
CALIFORNIA
United States
- Firm Profile
- Go to...
Elizabeth M. Richards

Position
Elizabeth Richards advises clients navigating the US Food and Drug Administration’s (FDA’s) oversight and regulation of the life sciences industry, including digital health, medical device, pharmaceutical, biotechnology, dietary supplement, food, cosmetic, and other life sciences industry clients.
Elizabeth counsels clients on regulatory, compliance, transactional, and legislative matters involving the FDA. Her practice spans all stages of the product life cycle, including with respect to:
-
- Pre-market product development and launch strategy
- Clinical trials and pre-clinical testing
- Product submissions
- Product marketing, promotion, and labeling
- Good manufacturing practice
- Agency inspections and recalls
- Enforcement actions
In addition to her focus on regulatory counseling and advocacy, Elizabeth frequently drafts and negotiates contracts with vendors of life sciences clients, including clinical trial sites, contract research organizations, contract manufacturers and laboratories, and suppliers. She also regularly advises on regulatory matters in connection with capital markets, financing, and M&A transactions involving FDA-regulated entities.
She currently serves as a member of the FDLI’s Medical Products Committee and served as an inaugural member of the FDLI Digital Health Committee, and has previously served on its Publications and Academic Programs Committee. Elizabeth is also a member of Latham’s Artificial Intelligence Task Force and the firm’s Digital Health Steering Committee, bringing together subject matter experts tracking developments in the rapidly evolving digital health space, and she participates as a member of the Medical Device Manufacturers Association’s FDA Working Group. Elizabeth also previously served as an Advisory Board member of the Children’s Law Center.
Lawyer Rankings
United States > Healthcare > Life sciences
(Next Generation Partners)Latham & Watkins LLP’s client base ranges from globally recognized life sciences businesses to biopharma and biotech start-ups. The busy practice is active across a range of life sciences industry sectors, from pharmaceuticals and biotechnology to cosmeceuticals and food tech. The team’s key areas of activity include complex corporate transactions such as M&A, with experts including Julie Scallen. Also on the transactional side, Shayne Kennedy focuses on capital markets along with Matthew Bush and Nathan Ajiashvili, while Cheston Larson advises on financing. Through its development of licensing structures and facilitation of commercial transactions, the team has been active in the funding of drug development and commercialization. The firm also handles litigation matters such as IP disputes, counting on experts such as Arlene Chow, as well as regulatory and legislative strategies; Ben Haas is a key figure in the latter. Among the practice’s key figures are also John Manthei
and Elizabeth M. Richards, both experts in FDA regulatory matters, and Terra Reynolds, in white-collar defense and investigations. In 2024, litigation and regulatory specialists Jennifer L. Bragg and William McConagha joined the practice from Skadden, Arps, Slate, Meagher & Flom LLP, and in April 2025, Kate Hillier joined from Cooley LLP.
Lawyer Rankings
- Life sciences United States > Healthcare
- Next Generation Partners United States > Healthcare > Life sciences
Top Tier Firm Rankings
- Insurance > Advice to policyholders
- Dispute resolution > Appellate: courts of appeals / Appellate: supreme courts (states and federal)
- Finance > Capital markets: debt offerings
- Finance > Capital markets: equity offerings
- Finance > Capital markets: global offerings
- Finance > Capital markets: high-yield debt offerings
- Antitrust > Cartel
- International trade and national security > CFIUS
- Antitrust > Civil litigation/class actions: defense
- Finance > Commercial lending
- Finance > Commercial lending: Advice to bank lenders
- Intellectual property > Copyright
- Media, technology and telecoms > Cyber law (including data privacy and data protection)
- Labor and employment > Employee benefits, executive compensation and retirement plans: transactional
- Energy > Energy transactions: electric power
- Energy > Energy transactions: oil and gas
- Environment > Environment: litigation
- Environment > Environment: regulatory
- Environment > Environment: transactional
- Finance > Fintech
- Dispute resolution > General commercial disputes
- Real estate > Land use/zoning
- Intellectual property > Patents: licensing
- Healthcare > Life sciences
- Dispute resolution > M&A litigation: defense
- M&A/corporate and commercial > M&A: large deals ($1bn+)
- Media, technology and telecoms > Media and entertainment: litigation
- Media, technology and telecoms > Media and entertainment: transactional
- Antitrust > Merger control
- International trade and national security > National Security
- Intellectual property > Patents: licensing
- Intellectual property > Patents: licensing
- Intellectual property > Patents: litigation (full coverage)
- Intellectual property > Patents: litigation (International Trade Commission)
- M&A/corporate and commercial > Private equity buyouts: large deals ($500m+)
- Dispute resolution > Product liability, mass tort and class action - defense: consumer products (including tobacco)
- Dispute resolution > Product liability, mass tort and class action - defense: toxic tort
- Finance > Project finance
- Real estate > Real estate
- Real estate > Real estate investment trusts (REITs)
- Energy > Renewable/alternative power
- Finance > Restructuring (including bankruptcy): corporate
- Dispute resolution > Securities litigation: defense
- M&A/corporate and commercial > Shareholder activism
- Industry focus > Sport
- Finance > Structured finance: derivatives and structured products
- Finance > Structured finance: securitization
- Media, technology and telecoms > Technology transactions
- Media, technology and telecoms > Telecoms and broadcast: regulatory
- Media, technology and telecoms > Telecoms and broadcast: transactions
- Intellectual property > Trade secrets (litigation and non-contentious matters)
- Tax > US taxes: contentious
- Tax > US taxes: non-contentious
- M&A/corporate and commercial > Venture capital and emerging companies
Firm Rankings
- M&A/corporate and commercial > Corporate governance
- International trade and national security > Customs, export controls and economic sanctions
- Industry focus > Education
- Energy > Energy regulation: electric power
- Energy > Energy regulation: oil and gas
- Government > Government contracts
- Insurance > Insurance: non-contentious
- Dispute resolution > International litigation
- Dispute resolution > Leading trial lawyers
- Investment fund formation and management > Private equity funds (including venture capital)
- Dispute resolution > Financial services litigation
- Healthcare > Health insurers
- Media, technology and telecoms > Outsourcing
- Healthcare > Service providers
- Dispute resolution > International arbitration
- Dispute resolution > Leading trial lawyers
- Intellectual property > Trademarks: litigation
- Dispute resolution > Leading trial lawyers
- Finance > Financial services regulation
- Finance > Commercial lending > Advice to direct lenders/private credit
- Dispute resolution > Corporate investigations and white-collar criminal defense